Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

AKBA stock hub

Akebia Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AKBAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

311.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AKBA

In the news

Latest news · AKBA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-79

P25 -105.6P50 -46.5P75 -3.1

ROIC3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AKBA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

225

Groups with data

Currency

USD

Showing 225 of 225 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001517022
Company name	Akebia Therapeutics, Inc.
Country	United States
Country code	US
Cusip	00972D105
Employees	194
Employees Change	13%
Employees Change Percent	7.18
Enterprise value	$346.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2014-03-20
Isin	US00972D1054
Last refreshed	2026-05-10
Market cap	$311.2M
Market cap category	Small-Cap
Price	$1.16
Price currency	USD
Rev Per Employee	1,197,958.76x
Sector	Healthcare
Sic	2834
Symbol	AKBA
Website	https://www.akebia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.59%
EV Sales Forward	1.62x
EV/EBIT	31.9x
EV/EBITDA	28.53x
EV/FCF	5.76x
EV/Sales	1.49x
FCF yield	19.29%
P/B ratio	11.35x
P/S ratio	1.34x
PS Forward	1.46x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	4.67%
EBITDA Margin	5.22%
FCF margin	25.83%
Gross margin	81.94%
Gross Profit	$190.4M
Gross Profit Growth	24.21%
Gross Profit Growth Q	-11%
Gross Profit Growth3 Y	-9.95%
Gross Profit Growth5 Y	-0.83%
Net Income	$-20.5M
Net Income Growth Years	1%
Pretax Margin	-8.07%
Profit Margin	-8.83%
Profit Per Employee	$-105,727
ROA	2.02
Roa5y	-9.1
ROCE	5.75
ROE	-78.96
ROIC	3.05

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-17.92%
Cagr1y	-52.87%
Cagr3y	2.1%
Cagr5y	-17.96%
EPS Growth Years	1
Revenue Growth	25.69x
Revenue Growth Q	-6.61x
Revenue Growth Years	1x
Revenue Growth3 Y	-4.98x
Revenue Growth5 Y	-2.15x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.69
Assets	$362.5M
Cash	$162.6M
Current Assets	$243.5M
Current Liabilities	$173.9M
Debt	$197.5M
Debt EBITDA	$11.53
Debt Equity	$7.22
Debt FCF	$3.29
Equity	$27.4M
Interest Coverage	0.51
Liabilities	$335.1M
Long Term Assets	$119M
Long Term Liabilities	$161.3M
Net Cash	$-34.9M
Net Cash By Market Cap	$-11.21
Net Debt EBITDA	$2.88
Net Debt Equity	$1.27
Net Debt FCF	$0.58
Tangible Book Value	$-31.7M
Tangible Book Value Per Share	$-0.12
WACC	7.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.4
Inventory Turnover	2.56
Net Working Capital	$-53.6M
Quick ratio	1.3
Working Capital	$69.6M
Working Capital Turnover	$2.55

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-86.12%
1Y total return	-52.85%
200-day SMA	2.04
3Y total return	6.42%
50-day SMA	1.39
50-day SMA vs 200-day SMA	50under200
5Y total return	-62.82%
All Time High	31
All Time High Change	-96.26%
All Time High Date	2014-06-20
All Time Low	0.24
All Time Low Change	381.33%
All Time Low Date	2022-10-24
ATR	0.1
Beta	0.35
Beta1y	0.29
Beta2y	0.95
Ch YTD	-27.95
High	1.2
High52	4.08
High52 Date	2025-07-11
High52ch	-71.56%
Low	1.13
Low52	1.13
Low52 Date	2026-05-08
Low52ch	3.11%
Ma50ch	-16.31%
Premarket Change Percent	-0.85
Premarket Price	$1.17
Premarket Volume	25,145
Price vs 200-day SMA	-43.05%
RSI	34.21
RSI Monthly	40.48
RSI Weekly	32.62
Sharpe ratio	-0.67x
Sortino ratio	-0.75
Total Return	-21.26%
Tr YTD	-27.95
Tr1m	-15.94%
Tr1w	-17.14%
Tr3m	-16.55%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	3
Analyst Price Target Top	$4.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.01
Earnings Revenue Estimate	52,629,760x
Earnings Revenue Estimate Growth	-8.21x
Operating Income	$10.8M
Operating margin	4.67
Price target	$4.67
Price Target Change	$303
Price Target Change Top	$303

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	262,583,928%
Float Percent	97.88%
Net Borrowing	-4,350,000
Shares Insiders	2.12%
Shares Institutions	46.8%
Shares Out	268,258,243
Shares Qo Q	0.63%
Shares Yo Y	21.26%
Short Float	10.4%
Short Ratio	11.07
Short Shares	10.18

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$47.3M
Average Volume	3,063,646.85x
Bv Per Share	0.1
CAPEX	$-335,000
Ch10y	-86.12
Ch1m	-15.94
Ch1w	-17.14
Ch1y	-52.85
Ch3m	-16.55
Ch3y	6.42
Ch5y	-62.82
Ch6m	-43.14
Change	-1.69%
Change From Open	-0.85
Close	1.18
Days Gap	-0.85
Depreciation Amortization	1,283,000
Dollar Volume	5,101,673
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$10.8M
EBITDA	$12.1M
EPS	$-0.08
F Score	5
FCF	$60M
FCF EV Yield	17.35x
FCF Per Share	$0.22
Financing CF	-2,941,000
Fiscal Year End	December
Founded	2,007
Goodwill	59,044,000
Income Tax	$1.8M
Investing CF	-8,142,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	1.67
Ma150ch	-30.5%
Ma20	1.41
Ma20ch	-17.73%
Net CF	49,289,000
Next Earnings Date	2026-08-06
Open	1.17
Optionable	Yes
P FCF Ratio	5.18
P OCF Ratio	5.15
Position In Range	46.67
Post Close	1.16
Postmarket Change Percent	0.86
Postmarket Price	$1.17
Ppne	3,421,000
Pre Close	1.18
Price Date	2026-05-08
Price EBITDA	$25.65
Relative Volume	1.44x
Revenue	232,404,000x
SBC By Revenue	5.49x
Share Based Comp	12,764,000
Tax By Revenue	0.75x
Tr6m	-43.14%
Us State	Massachusetts
Volume	4,397,994
Z Score	-4.43

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AKBA pay a dividend?

Capital-return profile for this ticker.

Performance

AKBA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AKBA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+46.8%

Float: +97.9% of shares outstanding

Insider ownership

+2.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AKBA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

34.2

Neutral momentum band

Price vs 200-day MA

-43.1%

50/200-day relationship not available

Beta (5Y)

0.35

Less volatile than the market

Sharpe ratio

-0.67

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AKBA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AKBA stock rating?

Akebia Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AKBA analysis?

The full report lives at /stocks/AKBA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AKBA?

The latest report frames AKBA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AKBA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.